CervoMed Inc (CRVO) USD0.001
Sell:$7.11Buy:$7.40
$0.57
(7.32%)
- This stock can be held in a
Stocks and Shares ISA$0.57
(7.32%)$0.57
(7.32%)Company Information
About this company
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. It is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.
Key people
Key facts
- EPICCRVO
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS15713L1098
- Market cap$68.49m
- Employees15
- Shares in issue8.70m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.